Haema 2010; 1(1): 103-109
by K. Liapis and J. Apostolidis
Haematology and Lymphoma Clinic “Evangelismos” Hospital, Athens, Greece
Abstract
Peripheral T cell lymphomas (PTCL) include a spectrum of disease entities that are rare and harbor a much poorer outcome after conventional chemotherapy than the more frequent B cell lymphomas. The experience from the use of myeloablative therapy with autologous or allogeneic stem cell transplantation is limited to retrospective data, subset analyses, and a few prospective multicenter studies in patients with diverse histologies and prognoses. Although subsets of patients, especially those with chemosensitive disease, benefit from high-dose therapy consolidated with an autologous or allogeneic transplant, phase ΙΙΙ prospective multicenter clinical trials are warranted to better discriminate who will benefit, and with which procedure.